Welcome to our dedicated page for Io Biotech SEC filings (Ticker: IOBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IO Biotech SEC filings document the company's transition from a Nasdaq-listed clinical-stage biopharmaceutical issuer to a Chapter 7 bankruptcy case after ceasing operations. The filings record trustee control over assets and liabilities, liquidation proceedings, related debt-default matters, and the limited recovery expectations disclosed for common stockholders.
Earlier filings cover quarterly operating updates, investor presentation materials, Nasdaq continued-listing compliance, workforce-reduction and exit-cost disclosures, officer and principal accounting officer changes, shareholder voting matters, capital-structure disclosures, governance matters, and clinical or regulatory updates tied to the company's T-win cancer vaccine programs.
Lundbeckfond Invest A/S, a major shareholder of IO Biotech, Inc., filed Amendment No. 2 to its Schedule 13D reporting its position and recent events at the company. Lundbeckfond Invest reports beneficial ownership of 21,851,920 shares of IO Biotech common stock, representing 27.4% of the class, based on 71,948,842 shares outstanding as of November 10, 2025. On March 31, 2026, IO Biotech ceased operations and filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware, and its assets will be liquidated with claims paid according to statutory priorities. On the same date, all members of IO Biotech’s board of directors, including Christian Elling, resigned from the board and its committees.
IO Biotech, Inc. reports that Reporting Person Jorey Chernett no longer beneficially owns any shares of common stock as of the close of business on May 19, 2026. The filing is an Amendment No. 2 to a Schedule 13G/A reflecting an exit filing.
The cover information lists the class as Common Stock, $0.001 par value (CUSIP 449778109). The signature block is dated 05/20/2026.
IO Biotech, Inc. amended a Schedule 13G to report that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen beneficially own 0% of the company's common stock as of the close of business on March 31, 2026. The filing lists the reporting persons and their Delaware/U.S. status.
HBM Healthcare Investments (Cayman) Ltd. reports beneficial ownership of 2,433,943 shares of IO Biotech, Inc. common stock, representing 3.3% of the class. This total includes 854,996 currently held shares and 1,578,947 shares issuable upon exercise of warrants at $2.47 per share, subject to a 9.99% beneficial ownership limitation. The percentage is calculated using 71,948,842 shares outstanding as of November 10, 2025.
IO Biotech, Inc. has ceased operations and filed a voluntary Chapter 7 bankruptcy petition in the U.S. Bankruptcy Court for the District of Delaware on March 31, 2026. A Chapter 7 trustee will take control of the company, liquidate assets, and pay creditors according to the Bankruptcy Code.
The company states it is unlikely that holders of its common stock will receive any payment or distribution from the bankruptcy proceedings. The filing triggers an event of default under a finance contract with the European Investment Bank, and all directors, officers, and employees have resigned or been terminated. IO Biotech will no longer be able to prepare or file its required SEC reports.
IO Biotech, Inc. reported that Nasdaq has notified the company it is not meeting the Nasdaq Global Select Market requirement that market value of listed securities be at least $50 million for 30 consecutive business days. This follows IO Biotech’s market value staying below that threshold.
The company has 180 calendar days, until August 11, 2026, to regain compliance. Nasdaq will consider the company compliant again if its market value of listed securities is at or above $50 million for at least ten consecutive business days during this period.
If IO Biotech does not regain compliance by the deadline, Nasdaq may initiate delisting of its common stock, though the company would have the opportunity to appeal under Nasdaq’s procedures. The notice does not immediately affect trading of IO Biotech’s shares, which continue on the Nasdaq Global Select Market.
IO Biotech, Inc. investor Jorey Chernett filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 4,543,532 shares of IO Biotech common stock, representing 6.3% of the class as of December 31, 2025.
Chernett reports sole voting and dispositive power over all 4,543,532 shares, with no shared voting or investment authority and no membership in a filing group. The certification states that the shares were not acquired to change or influence control of IO Biotech.
IO Biotech, Inc. received a Schedule 13G filing from Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen. They report beneficial ownership, through Point72 Associates, of 4,027,112 shares of IO Biotech common stock, representing 5.6% of the class as of February 5, 2026.
The reporting persons have shared voting and shared dispositive power over these shares and no sole voting or dispositive power. They state the securities were not acquired and are not held for the purpose of changing or influencing control of IO Biotech. The filing is made jointly under a Joint Filing Agreement.
IO Biotech, Inc. reported that its board approved a restructuring and workforce reduction plan intended to significantly cut operating expenses while the company explores a range of strategic alternatives. The plan is expected to result in a significant global reduction of the company’s workforce.
The company expects to incur one-time charges and cash expenditures of approximately $2.4 million to $2.6 million, mainly for wages, severance, healthcare continuation, earned vacation and related termination costs, primarily during the first quarter of 2026. IO Biotech also notified Chief Medical Officer Qasim Ahmad, M.D., a named executive officer, that his employment will end on February 15, 2026.
The company announced it has retained Raymond James & Associates, Inc. as exclusive financial advisor to assist in its ongoing exploration of strategic alternatives, and issued a press release describing the restructuring and workforce reduction plan, which is attached as an exhibit.
Novo Holdings A/S has reduced its stake in IO Biotech, Inc. This amendment reports that on January 21, 2026, Novo Holdings A/S sold 2,512,453 shares of IO Biotech common stock in open market transactions at prices ranging from $0.206 to $0.3903 per share, with a weighted average sale price of $0.2202 per share.
After these sales, Novo Holdings A/S beneficially owns 2,469,135 shares of IO Biotech common stock issuable upon the exercise of immediately exercisable warrants, representing approximately 3.3% of the company’s outstanding common stock based on 71,948,842 shares outstanding as of November 10, 2025. The filing states that Novo Holdings A/S ceased to be the beneficial owner of more than five percent of IO Biotech’s common stock on January 21, 2026.